Marc Dror Michaelson MD

Oncology•Boston, MA

Clinical Director, Genitourinary Cancer Center, Massachusetts General Hospital; Associate Professor of Medicine

Join to View Full Profile

55 Fruit StCox 640 Hematology OncologyBoston, MA 02114
Phone+1 617-726-5187
Fax+1 617-724-3166

Education & Training

Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2000 - 2002
Mass General Brigham/Brigham and Women's HospitalResidency, Internal Medicine, 1997 - 2000
Albert Einstein College of MedicineClass of 1997

Certifications & Licensure

MA State Medical License 1999 - 2026
NH State Medical License 2021 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer Start of enrollment: 2005 Jul 26
Completed
Phase 1, Phase 2
Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma Start of enrollment: 2007 Dec 01
Completed
Phase 2
Bevacizumab With or Without Sunitinib in Sunitinib-Refractory Renal Cell Carcinoma Start of enrollment: 2009 Sep 01
Withdrawn
Phase 2
Hormone Therapy, Radiation Therapy, and Steroid 17alpha-monooxygenase TAK-700 in Treating Patients With High-Risk Prostate Cancer
ACTIVE_NOT_RECRUITING
PHASE3
Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma Start of enrollment: 2013 Mar 08
Terminated
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

2 citations
Belzutifan plus cabozantinib as first-line treatment for patients with advanced clear-cell renal cell carcinoma (LITESPARK-003): an open-label, single-arm, phase 2 study.
Toni K Choueiri, Jaime R Merchan, Robert Figlin, David F McDermott, Edward Arrowsmith
The Lancet. Oncology. 2025-01-01
2 citations
Bladder-Preserving Trimodality Treatment for High-Grade T1 Bladder Cancer: Results From Phase II Protocol NRG Oncology/RTOG 0926.
Douglas M Dahl, Joseph P Rodgers, William U Shipley, M Dror Michaelson, Chin-Lee Wu
Journal of Clinical Oncology. 2024-12-01
Prognostic Significance of Immune Cell Infiltration in Muscle-invasive Bladder Cancer Treated with Definitive Chemoradiation: A Secondary Analysis of RTOG 0524 and RTO...
Zaker Rana, Sophia C Kamran, Amol C Shetty, Philip Sutera, Yang Song
European Urology Oncology. 2024-10-01